ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,323.00
-0.04%
S&P ASX All Technology
3,880.20
0.04%
Brent Oil
73.125
0.39%
US Dollar vs AUD
1.5357
0.00%
Bitcoin
97,258.22
3.07%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Anavex Life Sciences Corporation (AVXL) Share Price

Anavex Life Sciences Corporation

Anavex Life Sciences Corporation (AVXL)

NASDAQ
8.475
0.235
(2.85%)
Closed 21 November 8:00AM
Delayed by 15 minutes
8.45
-0.025
(-0.29%)
After Hours: 11:12AM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
8.45
Bid
8.45
Offer
8.50
Volume
898,849
8.05 Day's Range 8.48
3.25 52 Week Range 10.45
Market Cap
716.522M
Previous Close
8.24
Open
8.27
Last Trade
10
@
8.46
Last Trade Time
Financial Volume
US$ 7,441,334
VWAP
8.2787
Average Volume (3m)
971,614
Shares Outstanding
84,795,517
Dividend Yield
-
PE Ratio
-15.14
Earnings Per Share (EPS)
-0.56
Revenue
-
Net Profit
-47.51M

About Anavex Life Sciences Corporation

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are u... Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.anavex.com
Headquarters
Carson City, Nevada, USA
Founded
-
Anavex Life Sciences Corporation is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker AVXL. The last closing price for Anavex Life Sciences was US$8.24. Over the last year, Anavex Life Sciences shares have traded in a share price range of US$ 3.25 to US$ 10.45.

Anavex Life Sciences currently has 84,795,517 shares in issue. The market capitalisation of Anavex Life Sciences is US$698.72 million. Anavex Life Sciences has a price to earnings ratio (PE ratio) of -15.14.

Ask ADVFN Intelligence (AI)

AVXL Latest News

More News

Anavex’s Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer’s Trial: Data Presented at CTAD Conference 2024

Data of Blarcamesine confirm upstream SIGMAR1 activation Presented as Late Breaking Oral Communications at Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2024 Oral, once daily...

31 October 2024
GlobeNewswire Inc.

ZenaTech, Inc. (NASDAQ: ZENA) Software Company Acquisition

ZenaTech, Inc. (NASDAQ: ZENA) Software Company Acquisition     Miami, FL – October 23, 2024 -- InvestorsHub NewsWire – EmergingGrowth.com, a leading...

23 October 2024
InvestorsHub NewsWire

Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia

Part A of the placebo-controlled Phase 2 study has been completed ANAVEX®3-71 demonstrates a dose-dependent pharmacodynamic effect on objective EEG biomarkers of schizophrenia Patients are...

17 October 2024
GlobeNewswire Inc.

ZenaTech, Inc. (NASDAQ: ZENA) First US Trial of IQ Nano Drone for Inventory Management

ZenaTech, Inc. (NASDAQ: ZENA) First US Trial of IQ Nano Drone for Inventory Management  Commercial Drone market expected to grow at 23.7 CAGR (Compound Annual Growth Rate) through...

15 October 2024
InvestorsHub NewsWire

ZenaTech, Inc. (NASDAQ: ZENA) To Commence Trading Today

ZenaTech, Inc. (NASDAQ: ZENA) To Commence Trading Today   Commercial Drone market expected to grow at 23.7 CAGR (Compound Annual Growth Rate) through 2030     Miam...

01 October 2024
InvestorsHub NewsWire

Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024

NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated...

03 September 2024
GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

07 August 2024
Edgar (US Regulatory)

Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update

Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage...

06 August 2024
GlobeNewswire Inc.

Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024

NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated...

01 August 2024
GlobeNewswire Inc.

Form 8-K - Current report

31 July 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.7-7.650273224049.159.397.1814805137.91606281CS
42.8651.16279069775.5910.455.2216120237.57499998CS
122.3939.43894389446.0610.454.93019716146.66229614CS
263.8684.09586056644.5910.453.5110482235.7898344CS
521.4520.7142857143710.453.2512085265.83115036CS
156-11.907-58.490936778520.35721.33.2511619508.74003668CS
2606.05252.0833333332.431.52.2131549410.41356819CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
FBRXForte Biosciences Inc
US$ 13.60
(129.53%)
29.6M
QSIQuantum Si Inc
US$ 1.39
(119.59%)
283.09M
XCURExicure Inc
US$ 11.01
(89.18%)
22.93M
AGFYAgrify Corporation
US$ 37.4635
(68.00%)
924.44k
SLXNSilexion Therapeutics Corporation
US$ 0.3495
(54.51%)
200.06M
SKKSKK Holdings Limited
US$ 4.55
(-47.28%)
816.93k
QMMMQMMM Holdings Limited
US$ 0.713999
(-43.78%)
4.61M
XTKGX3 Holdings Company Ltd
US$ 0.0901
(-37.82%)
5.95M
PRFXPainReform Ltd
US$ 1.02
(-27.14%)
5.09M
GLEGlobal Engine Group Holding Ltd
US$ 3.81
(-26.59%)
230.23k
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0.191
(17.39%)
662.68M
DBGIDigital Brands Group Inc
US$ 0.1345
(15.35%)
326.45M
NVDANVIDIA Corporation
US$ 145.89
(-0.76%)
309.57M
QSIQuantum Si Inc
US$ 1.39
(119.59%)
283.09M
SLXNSilexion Therapeutics Corporation
US$ 0.3495
(54.51%)
200.06M

AVXL Discussion

View Posts
Steady_T Steady_T 2 hours ago
How's that rent collection going? 🤣
👍️ 2
georgejjl georgejjl 3 hours ago
When discussing "muscarinic M1" in relation to schizophrenia and PANSS, it refers to the potential therapeutic role of activating the M1 subtype of muscarinic acetylcholine receptors as a novel treatment strategy for schizophrenia, where improvements in symptoms can be measured using the Positive and Negative Syndrome Scale (PANSS), with research showing that targeting M1 receptors may lead to significant reductions in PANSS scores, indicating symptom improvement in patients with schizophrenia.

Anavex 3-71 for the treatment of schizophrenia.

Good luck and GOD bless,
👍️0
ExtremelyBullishZig ExtremelyBullishZig 3 hours ago
You believe George after the crap he pulls on a daily basis?
👎️ 1 👺 1
georgejjl georgejjl 3 hours ago
I will predict that AVXL should exceed the $1 Billion market capitalization next week.

Good luck and GOD bless,
👍️0
boi568 boi568 3 hours ago
You are thinking more like a manager than an investor in a speculative stock.
👍️ 3
kund kund 3 hours ago
Pumper Mayo pumping JPM news, which clown CEO posted on linkedin and X 3 month in advance, as if that is any indication. He pumped model picture with Elon's mom sometime back.
👎️ 1 👺 1
kund kund 3 hours ago
You didn't get the memo? New video has surfaced, most probably from that tiny phase 2a trial, super responders.

https://vimeo.com/1023753471
👎️ 1 👺 1
georgejjl georgejjl 3 hours ago
An Australian TV news interview of Ern Heaven and his wife. Ern had Alzheimer's for over 2 years and was declining when he joined the Anavex phase 2a trial of Anavex 2-73. Over a period of a year on the drug, he first stabilized, and then improved. No other drug has ever helped an Alzheimer's patient improve.

According to the 1 year trial results, 6 patients out of the initial 32 had "strong" reactions and showed improvements in one or more tests.



Good luck and GOD bless,
👍️0
La Flaca La Flaca 4 hours ago
We all stumbled onto this drug and didn’t really appreciate its value - starting with the Greek doctor and Missling. We all hung around because we hoped and prayed that it would work. Earlier and better execution would have been great but it is what it is. Looks like it works - better than anything that’s out there. Let’s hope it gets approved soon for the sake of the families afflicted with early alz. The money will come.
🎯 1 👍️ 7
crescentmotor crescentmotor 4 hours ago
to have submitted something 4 months later than it nominally should have while moving the ball forward on none of the other programs is shameful.

Dr. Missling is a proven underperformer. It's even worse than that as he has mislead AVXL's shareholders for a number of years with shameful shareholder guidance. I don't see how anyone with a properly functioning brain could argue that fact. It is nothing but horrible performance that the AD OLE data has not been released, not to mention the MAA. The word "slow" comes to mind that doesn't seem adequate. I will be very pleased if the MAA is filed and moves forward. After that, a partnership/buyout could occur and Dr. Missling would most likely be put out to pasture.
👎️ 1 👺 2
bas2020 bas2020 4 hours ago
You're absolutely correct. I saw through that masquerade for quite a while. Another to add to the list.
👍️ 5
georgejjl georgejjl 4 hours ago
I predict that the dosing of all trial participants in the Phase 2 schizophrenia trial will be completed during or prior to December 2024.

https://www.anavex.com/post/anavex-life-sciences-announces-encouraging-preliminary-biomarker-results-from-ongoing-phase-2-study#:~:text=NEW%20YORK%20–%20October%2017%2C%202024&text=Part%20A%20of%20the%20Phase,mg%20daily%20for%2010%20days.

Good luck and GOD bless,
🎯 1 👍️ 2
ignatiusrielly35 ignatiusrielly35 5 hours ago
An extremely subtle fudster has revealed himself or herself. 
👍️ 6
Hoskuld Hoskuld 5 hours ago
Yes - to have submitted something 4 months later than it nominally should have while moving the ball forward on none of the other programs is shameful. It is a win - but is severe underperformance. For a pumper like yourself, everything is perfect, I get that.
👍️ 3 👎️ 3 👺 5 ❌️ 2
Hosai Hosai 5 hours ago
"As you wrote, they will either submit the MAA or they won't...but submitting it by YE is a hollow win".

An AD MAA for Europe where only a handful of AD drugs have been approved in decades, which has high approval rates due to a lot of discussions and vetting pre-submission and for which approval would likely mean massive revenues and subsequant share price increase equals "a hollow win"?
👍️ 11
ignatiusrielly35 ignatiusrielly35 6 hours ago
Artificial deadlines are only important if they have some substantive consequence. In which case they would not be artificial. But I digress. 

I would feel so much better, if I was short or wrote covered calls, if the EMA filing doesn't occur by x date that would necessarily mean that the data suddenly suck and/or the filing will not occur within y weeks of x date, or ever. Load the short boat. 

If my wife doesn't come home from work as predicted that means she's likely dead from a car accident. 
👍️ 1 👎️ 1 👺 1
WilliamMunny WilliamMunny 6 hours ago
Actually, power, Anavex has 90 days to file its 10-K this year. Unlike 2022 and 2023, the company's public float was under $700 million on the last day of FQ2, so it is no longer a "large accelerated filer," at least as I read it. Therefore the 10-K (and PR/conference call) in December is no problem for the SEC, whether it is the first business day of Advent or Christmas Eve. Particularly since Thanksgiving is late in the month and would interfere with the PR and conference call, I can't imagine a 10-K filing in November.
👍️ 4
Hoskuld Hoskuld 6 hours ago
LF, they have inexplicably abandoned every other initiative they initially said they would make progress on this year: no PD, no secret indication, no Rett, no [fill in the blank]... They have inexplicably poured everything into this one document and they have not finished it yet and have maybe 15 business days left to do so. IMO, they have wasted another whole year with the exception of schizophrenia program - whose p2 is so tiny that I don't think even tremendous success will lift the share price and create value...

As you wrote, they will either submit the MAA or they won't...but submitting it by YE is a hollow win: the value of the asset is worn away by yet another year. This is just not done in biopharma - executives work their tails off to maximize the most important asset: time.
👍️ 4 👺 1
Hoskuld Hoskuld 6 hours ago
If they had submitted then they would announce. This is a company that has never met a self-imposed timeline and had a terrible failure with Rett program. It was supposed to do so much this year and has done nothing. If they had anything even resembling a win they would PR it immediately.
👍️ 4 👺 1
Investor2014 Investor2014 7 hours ago
Yes and otherwise we are into Feb'ish.
👎️ 1 👺 1
La Flaca La Flaca 7 hours ago
Just trying to piece everything together. AVXL has an opportunity to announce either the start date of 11/28 (which means the MAA was filed and accepted) or the filing of the MAA 11/25, in Dec. and they’d meet their commitment / deadline to file inQ4.
👍️ 4
Investor2014 Investor2014 8 hours ago
The chance of that being true is even better than the rumour of a tea pot orbiting Mars, which could be true. Alas as yet we just can't prove or disprove it.
👍️ 1 👎️ 1 👺 1
Hoskuld Hoskuld 8 hours ago
Maybe it was approved and they are secretly selling 2-73 in Lichtenstein right now. We don't know that is not happening, right?
👎️ 1 👺 3
La Flaca La Flaca 8 hours ago
I should clarify that I don't know for a fact that they haven't filed. Maybe they have and will PR the start date of 11/28 referenced by Hosai. 🤨
👋 1 👍️ 1
La Flaca La Flaca 8 hours ago
I'm optimistic. They will either make or miss the deadline for what appears to be the last date of submission with EMA in 2024.

👍️ 2 🤔 1
CkFacts CkFacts 9 hours ago
CHMP is a committee of the EMA , and is responsible for the scientific evaluation of the application dossier . After thorough review of the data the CHMP issues it opinion ( positive or negative ) to the EMA . If review is positive the EMA sends recommendation for approval to European Commission.
👋 2 👍️ 3
Hoskuld Hoskuld 9 hours ago
PW you are spot on. The hype in the post, too, is silly: a report needs to be made and it will be made - there is no promise of anything more than the necessary report.
👍️ 1
kund kund 9 hours ago
Anavex has 75 days to file 10k, company market cap was less than $700mil at the end of fiscal year. ST poster is correct, but there is nothing much to read into it, buffoon want to delay everything as much as possible.
👺 1 ❌️ 1
powerwalker powerwalker 9 hours ago
You trust him why? He is full of s**t ... He did NOT speak to IR. As george noted, it is a 10-K being filed, not the Q, and I believe Anavex has to file within 60 days, which is November 29th. If they don't, they need to file with SEC and explain why.
👍️ 5
Hosai Hosai 9 hours ago
The CHMP meetings are just where they discuss applications that have already been accepted as MAAs as far as I understand.
I don't believe the CHMP is involved in the 2-3 week period when a submission is processed and 'accepted' and given a start date. It's a more basic administrative checklist exercise. There is no scientific evaluation here.
CHMP were involved in the eligiblity to submit an application stage which AVXL already passed obv.
👍️ 7
CkFacts CkFacts 9 hours ago
Next CHMP meetings Dec 9-12 ,2024 , Jan 27-30 2025
👋 1 👍️ 2
ExtremelyBullishZig ExtremelyBullishZig 10 hours ago
LOL
👎️ 1 👺 1
Hosai Hosai 11 hours ago
I believe the last 2 start dates of this year will be around Nov 28th and Dec 27th going from previous MAA start dates recently and in prior years in that ongoing CHMP apps tracker s/s. Usually the acceptance PR is on the day of the start date or a few days after it.
👍️ 5
Investor2014 Investor2014 12 hours ago
It would make sense for Anavex to announce an accepted MAA, which might be doable in December provided of course the company has actually filed one.
👍️ 2 👎️ 1 👺 1
georgejjl georgejjl 12 hours ago
La Flaca,

It is NOT a 10Q will be a 10K, since Anavex Life Sciences fiscal year ended on September 30, 2024.

Good luck and GOD bless,
👍️0
La Flaca La Flaca 12 hours ago
Brian5220 from stocktwits:

"Okay... Just got off the phone with Anavex IR. They will give a weeks notice before the 10-Q release. IR states it will be in December. Not next week for the conference call or release of the 10-Q."

Cancel your sell limit. Don't say no one warned you. 🙏





👍️ 1 🤔 2
BDR10 BDR10 12 hours ago
Aren't we all here for the same reason there's no need to have all the fighting and arguing on the board can't we all just get along LOL
👍️ 2
Hoskuld Hoskuld 12 hours ago
No. Trial size adequacy is NOT baked into the p values. (little p instead of big because it is lowercase rho that = stat sig.) So why is this not true? Answer: because for huge indications, like AD, you need a huge sample set to be sure of safety. It is possible that Anavex can overcome this with OLE data and safety data from Rett and other trials.

You could (easily) say the trial size was inadequate because ADL impact (one of only two primary endpoints) was not stat sig and adding even another 100 patients would have pushed it where it needed to be.

No one should have a bias where they think everything is honky dory with respect the Anavex and its trials designs and executions. We all want our stock investment to succeed but it doesn't do us any good to only see rainbows and unicorns whenever we examine Anavex's track record.

Anavex still hasn't done a damn thing. LFG Anavex - execute now please.
👍️ 6
powerwalker powerwalker 13 hours ago
Very nice find, badger. Surprised it took 20+ days for us to see it, given the number of "all things Anavex" people who keep an eye out for publications. It would be good to know which trial these folks are from" P2a or P2b/3 or if it is a mix. More of these testimonials would be great to see.
👍️ 7
Hosai Hosai 13 hours ago
"Isn't the trial size adequacy baked into the P values? Seems like form over substance to me. The fact that other companies with drugs having marginal effect chose to run two large pivotals is that important?"

Exactly...the 0.008 p value for ADAS COG in ITT means if you ran a trial on a sugar pill vs placebo 1,000 times you would only get a result as extreme as was found between Blarca and placebo 8 times out of that 1,000 trials.

Then there is p values for CDR SB - 0.01
CGI-I - 0.003
Grey matter retention - 0.0035
Whole brain - 0.0019
Lateral ventricles - 0.0015.
Plasma amyloid beta 42/40 - 0.048

Even the non-stat sig plasma findings had large effect sizes in Blarcamesines favour, but must have had huge variations between high and low in each cohort to mean not stat sig. They actually are on par with the effect size difference for grey matter vs placebo - 63.5%.

Plasma reductions vs placebo that were not stat-sig:
Nf-L - 67% reduction (p=0.28)
P-Tau 181 - 64% reduction (p=0.39)
P-Tau 231 - 92% reduction (p=0.44)
👍️ 6
sab63090 sab63090 13 hours ago
Not much new to read on this message board, same old biased viewpoints, so here's a couple of things to consider:

The price has definitely found some sort of support and I noticed that the MACD has corrected back to the black line to kiss that spot which is a noticeable "kiss" which often works as a short term "buy spot"....Kennedy from Elliott Wave has mentioned it often in the past. The RSI has certainly worked off the overbought level. I agree with Tom about short term resistance @ 8.35 to 8.40 and it seems to be challenging the down slope right now; looks potentially bullish if we are able to push up past it!

The OBV especially on the Weekly Chart looks good to me from that low at appx $3.50 to now...it's been going up consistently!

The sole negative, so far, is the lack of VOLUME and price push up!
👍️ 4
williamssc williamssc 13 hours ago
That corner your painting yourself into is getting smaller
👍️ 4 😃 2
sab63090 sab63090 13 hours ago
I just am replying to you as I just got back home and I try to answer any message I received first....seeing some things and will comment on in a few minutes!
👍️ 3
ExtremelyBullishZig ExtremelyBullishZig 13 hours ago
This sure provided a ton of shareholder value. I am grateful for the news Anavex provided about the fireside chat presentations today.
👎️ 1 👺 1
sab63090 sab63090 13 hours ago
Just got back home and I am seeing several interesting things which I will post on after I catch up on the board!
👍️ 1
kund kund 14 hours ago
There always seems to be a pattern with this CEO—using various means to pump the stock before eventually revealing the drug's sucks. Until the company files for regulatory approval and the drug gets approved, there's little to no real value in this company.
👍️ 1
BIOChecker4 BIOChecker4 14 hours ago
So please do tell us: How many thousands of shares are you buying in anticipation of news between tomorrow and next week? Are you putting your money where your mouth is?

Perhaps a better question is: How many shares are you planning to sell once the stock runs up on anticipation of HUGE NEWS?

By the way, thank you for repeatedly reminding everyone of all the 2H events that are not going to happen.
👍️ 1 👺 1
ignatiusrielly35 ignatiusrielly35 14 hours ago
Isn't the trial size adequacy baked into the P values? Seems like form over substance to me. The fact that other companies with drugs having marginal effect chose to run two large pivotals is that important?
👍️ 6
123tom 123tom 14 hours ago
Resistance now today around 8.40/8.30
👍️ 1
sage4 sage4 14 hours ago
The video was posted 24 day ago. 
So let's not worry. Lol
👍️ 1

Your Recent History

NASDAQ
AVXL
Anavex Life Sciences
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved